We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for alectinib (Roche Products Pty Limited)
Active ingredients
alectinib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Registration date